Correspondence 0001193125-23-210948 from 4D Molecular Therapeutics, Inc. (FDMT) (CIK 0001650648) (FDMT)
4D Molecular Therapeutics, Inc. (FDMT) (CIK 0001650648)
Date: Aug. 11, 2023 · CIK: 0001650648 · Accession: 0001193125-23-210948
AI Filing Summary & Sentiment
File numbers found in text: 333-273845
Letter
4D Molecular Therapeutics, Inc.
5858 Horton Street, #455
Emeryville, California 94608
August 11,
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Jason Drory
Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-273845)
To the addressee set forth above:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333-273845) (the “Registration Statement”) of 4D Molecular Therapeutics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 15, 2023, or as soon as practicable thereafter, or at such other time thereafter as our counsel, Latham & Watkins LLP may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Mark Roeder at (650) 463-3043 or Phillip Stoup at (415) 395-8216.
Thank you for your assistance in this matter.
Very truly yours,
4D MOLECULAR THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP 4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 August 11, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jason Drory Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-273845) To the addressee set forth above: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333-273845) (the “Registration Statement”) of 4D Molecular Therapeutics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 15, 2023, or as soon as practicable thereafter, or at such other time thereafter as our counsel, Latham & Watkins LLP may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Mark Roeder at (650) 463-3043 or Phillip Stoup at (415) 395-8216. Thank you for your assistance in this matter. Very truly yours, 4D MOLECULAR THERAPEUTICS, INC. By: /s/ August Moretti August Moretti Chief Financial Officer cc: David Kirn, M.D., 4D Molecular Therapeutics, Inc. Scott Bizily, J.D., Ph.D., 4D Molecular Therapeutics, Inc. Mark V. Roeder, Latham & Watkins LLP Phillip S. Stoup, Latham & Watkins LLP